GGCX and coronary artery disorder: By using colocalization analyses, the directional effects of the candidate causal SNP between vascular gene expression and CAD-risk suggest that the inhibition of 4 genes may lower disease-associated risk (PDGFD, IPO9, GGCX, CETP). As an example, among the potential drug targets, PDGFD encodes for platelet derived growth factor D. In the aorta, colocalization between eQTL for PDGFD and CAD-GWAS (PP = 0.99) suggests a causal association and prioritizes gene variant rs974819 (Fig. 4C).